Program
trilaciclib
Also written as “Trilaciclib” and “Trilaciclib, carboplatin, etoposide,or Topotecan”.
Its studies are mostly in Small Cell Lung Carcinoma · Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharmacosmos | 112 open or running | phase 4since Apr 12, 2023 | Jul 8, 2015 | Oct 31, 2027phase 3 · NCT07473128 |
| Simcere Pharmaceutical Group | 31 open or running | phase 4since Sep 28, 2021 | May 8, 2021 | Jul 15, 2027phase 3 · NCT07881705 |
Also a collaborator on its studies: roche-genentech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2015First studies: 2 phase 2 studies in Small Cell Lung CarcinomaNew to PharmacosmosPharmacosmos · NCT02499770, NCT02514447
- Feb 1, 2017Phase 2 study in Small Cell Lung CarcinomaPharmacosmos · NCT03041311 · 107 enrolled · United States, Bulgaria, Estonia and more
- Oct 20, 2020Phase 3 study in Colorectal NeoplasmsPharmacosmos · NCT04607668 · 326 enrolled · United States, China, Hungary and more
- Feb 18, 2021Phase 3 study in Triple Negative Breast NeoplasmsPharmacosmos · NCT04799249 · 194 enrolled · United States, Australia, Bulgaria and more
- Apr 16, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungPharmacosmos · NCT04863248 · 10 enrolled · United States
- May 5, 2021Phase 2 study in Carcinoma, Transitional CellPharmacosmos · NCT04887831 · 92 enrolled · United States, France, Georgia and more
- May 8, 2021Simcere Pharmaceutical Group's first study: phase 3 study in Small Cell Lung CarcinomaNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT04902885 · 95 enrolled · China
- Sep 28, 2021Phase 4 study in Small Cell Lung CarcinomaSimcere Pharmaceutical Group · NCT05071703 · 30 enrolled · China
- Oct 6, 20212 phase 2 studies in Triple Negative Breast NeoplasmsPharmacosmos · NCT05112536, NCT05113966
- Apr 12, 2023Phase 4 study in Small Cell Lung CarcinomaPharmacosmos · NCT05874401 · 302 enrolled · Spain
- Mar 5, 2026Phase 3 study in Limited Stage Small Cell Lung CancerPharmacosmos · NCT07473128 · 120 planned · United States
- Oct 2, 2026Primary completion moved from 2027-06 to 2027-10-31Date moved laterphase 3 · +5 months · NCT07473128
- Oct 5, 2026Primary completion moved from 2027-10-30 to 2028-02-05Date moved laterphase 4 · +3 months · NCT05874401
- Oct 12, 2026Phase 3 study in Small Cell Lung CarcinomaSimcere Pharmaceutical Group · NCT07881705 · 106 enrolled · China
Ahead
- Jul 15, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaSimcere Pharmaceutical Group · NCT07881705
- Oct 31, 2027Primary completion: phase 3 study in Limited Stage Small Cell Lung CancerPharmacosmos · NCT07473128
- Feb 5, 2028Primary completion: phase 4 study in Small Cell Lung CarcinomaPharmacosmos · NCT05874401
TargetBeta
“A small molecule, competitive inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), ”NCIt, by rule
“Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor; Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07881705Small Cell Lung Carcinoma · China | 3 | Active, not recruiting | Simcere Pharmaceutical Group | Jul 15, 2027 | 106 |
| NCT07473128Limited Stage Small Cell Lung Cancer · United States | 3 | Recruiting | Pharmacosmos | Oct 31, 2027 | 120 |
| NCT05874401Small Cell Lung Carcinoma · Spain | 4 | Active, not recruiting | Pharmacosmos | Feb 5, 2028 | 302 |
| NCT05113966Triple Negative Breast Neoplasms · United States | 2 | Terminated | Pharmacosmos | Nov 10, 2023 | 30 |
| NCT05112536Triple Negative Breast Neoplasms · United States | 2 | Completed | Pharmacosmos | Oct 31, 2022 | 24 |
| NCT05071703Small Cell Lung Carcinoma · China | 4 | Completed | Simcere Pharmaceutical Group | Apr 10, 2022 | 30 |
| NCT04902885Small Cell Lung Carcinoma · China | 3 | Completed | Simcere Pharmaceutical Group | Dec 29, 2021 | 95 |
| NCT04887831Carcinoma, Transitional Cell · United States, France, Georgia and more | 2 | Terminated | Pharmacosmos | Apr 7, 2023 | 92 |
| NCT04863248Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Pharmacosmos | Feb 2, 2022 | 10 |
| NCT04799249Triple Negative Breast Neoplasms · United States, Australia, Bulgaria and more | 3 | Completed | Pharmacosmos | May 24, 2024 | 194 |
| NCT04607668Colorectal Neoplasms · United States, China, Hungary and more | 3 | Terminated | Pharmacosmos | Feb 13, 2023 | 326 |
| NCT03041311Small Cell Lung Carcinoma · United States, Bulgaria, Estonia and more | 2 | Completed | Pharmacosmos | Aug 17, 2018 | 107 |
| NCT02514447Small Cell Lung Carcinoma · United States, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Pharmacosmos | Sep 28, 2018 | 123 |
| NCT02499770Small Cell Lung Carcinoma · United States, France, Georgia and more | 2 | Completed | Pharmacosmos | Jul 3, 2017 | 122 |
How it is read
Names in the registry
- “Trilaciclib”, 13 entries
- “Trilaciclib, carboplatin, etoposide,or Topotecan”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 8 studies
- Triple Negative Breast Neoplasms, 3 studies
- Carcinoma, Transitional Cell, 1 study
- Colorectal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.